Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Triptorelin Pamoate

FDA-approved product (injectable, intramuscular), marketed as Trelstar, Triptodur Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Triptorelin Pamoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Central precocious puberty
  • Metastatic prostate cancer
  • Neoplasm
  • Precocious puberty
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Triptorelin Pamoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Triptorelin Pamoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

    NCT00567580 · start 2008-02

    Registered record
    Registry ID
    NCT00567580
    Conditions
    Prostate Cancer
    Interventions
    PBRT; PLNRT; AA; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    1,792

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPBRT; PLNRT; AA; LHRH agonist
    PhasePhase 3
    Registry statusUnknown

  • Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

    NCT00090844 · start 2004-07

    Registered record
    Registry ID
    NCT00090844
    Conditions
    Breast Cancer; Hormone Changes; Drug Toxicity
    Interventions
    triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-07
    Completion
    2008-05
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Hormone Changes; Drug Toxicity
    Interventiontriptorelin
    PhasePhase 2
    Registry statusTerminated

  • Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

    NCT00066690 · start 2003-12-17

    Registered record
    Registry ID
    NCT00066690
    Conditions
    Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer
    Interventions
    Exemestane; Laboratory Biomarker Analysis; Oophorectomy; Quality-of-Life Assessment; Radiation Therapy; Tamoxifen; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12-17
    Completion
    2024-11-06
    Enrolment
    3,066

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer +4 more
    InterventionExemestane; Laboratory Biomarker Analysis; Oophorectomy; Quality-of-Life Assessment +3 more
    PhasePhase 3
    Registry statusCompleted

  • Premenopausal Endocrine Responsive Chemotherapy Trial

    NCT00066807 · start 2003-08

    Registered record
    Registry ID
    NCT00066807
    Conditions
    Breast Cancer
    Interventions
    chemotherapy; exemestane; tamoxifen; triptorelin; oophorectomy; ovarian irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-08
    Completion
    2006-12
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionchemotherapy; exemestane; tamoxifen; triptorelin +2 more
    PhasePhase 3
    Registry statusTerminated

  • Hormone Therapy in Treating Patients With Advanced Prostate Cancer

    NCT00003026 · start 1997-04

    Registered record
    Registry ID
    NCT00003026
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; flutamide; triptorelin; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-04
    Completion
    Not recorded
    Enrolment
    966

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; flutamide; triptorelin; radiation therapy
    PhasePhase 3
    Registry statusCompleted